title: The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer.
abstract: Although selective estrogen receptor modulators (SERMs), such as tamoxifen, or aromatase inhibitors (AIs), such as anastrozole, are the preferred endocrine treatment approach for most patients with hormone receptor-positive breast cancer, many patients progress despite this therapy or become resistant. Fulvestrant is a selective estrogen receptor down-regulator (SERD) that has demonstrated activity and efficacy in patients with hormone receptor-positive breast cancer previously untreated or treated with hormonal therapy. The efficacy of fulvestrant has been demonstrated in the neoadjuvant and metastatic settings, either alone or in combination with other therapies such as anastrozole or targeted drugs. Additionally, 500 mg of fulvestrant have been shown to be more effective than 250 mg, without significant differences in the toxicity profile. In this review, the unique mode of action of fulvestrant and the clinical data for different dosing regimens both alone or in combination with other drugs is critically assessed.
authors.affiliation: Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: eva.ciruelos@gmail.com.
authors.forename: Eva
authors.initials: E
authors.lastname: Ciruelos
authors.affiliation: Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: tomaspascualmartinez@hotmail.com.
authors.forename: Tomás
authors.initials: T
authors.lastname: Pascual
authors.affiliation: Gynecology and Obstetrics Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: mlarroyov@yahoo.es.
authors.forename: María Luisa
authors.initials: ML
authors.lastname: Arroyo Vozmediano
authors.affiliation: Gynecology and Obstetrics Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: whitepontevedra@hotmail.com.
authors.forename: Marta
authors.initials: M
authors.lastname: Blanco
authors.affiliation: Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: luis_manso@hotmail.com.
authors.forename: Luis
authors.initials: L
authors.lastname: Manso
authors.affiliation: Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: luciaprubio@hotmail.com.
authors.forename: Lucía
authors.initials: L
authors.lastname: Parrilla
authors.affiliation: Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: burpee@hotmail.com.
authors.forename: Cesar
authors.initials: C
authors.lastname: Muñoz
authors.affiliation: Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: estela_1983@hotmail.com.
authors.forename: Estela
authors.initials: E
authors.lastname: Vega
authors.affiliation: Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: mjca46@hotmail.com.
authors.forename: Monica Jackelin
authors.initials: MJ
authors.lastname: Calderón
authors.affiliation: Gynecology and Obstetrics Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: bsancho.hdoc@salud.madrid.org.
authors.forename: Blanca
authors.initials: B
authors.lastname: Sancho
authors.affiliation: Medical Oncology Department, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, 28041 Madrid, Spain. Electronic address: hcortes_funes@oncocenter.com.
authors.forename: Hernán
authors.initials: H
authors.lastname: Cortes-Funes
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D065171:Estrogen Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D017063:Outcome Assessment, Health Care; D011960:Receptors, Estrogen / Q000378:metabolism*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D065171:Estrogen Receptor Antagonists; D011960:Receptors, Estrogen; D020845:Selective Estrogen Receptor Modulators; D000077267:Fulvestrant; D004958:Estradiol
keywords: Aromatase inhibitor; Endocrine treatment; Fulvestrant; Hormone receptor-positive breast cancer; Selective estrogen receptor down-regulators; Selective estrogen receptor modulators